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Approaches to the genetics of cardiovascular disease through genetic
field work. Successful molecular genetic studies of complex disease require
exact, careful phenotypization, which is more difficult than that performed
for monogenic diseases. We have developed a family-oriented field
working approach, which relies on index patients, their primary care
physicians, and a minimum number of field working staff. The patients are
responsible for recruiting their family members. Packets containing an
explanatory pamphlet, an informed consent statement, a questionnaire,
and blood cuvettes are provided. Data are transferred from questionnaire
and from the laboratory into a computer program that facilitates construc-
tion of the family tree. We have applied this genetic field working
approach primarily to patients with lipid disorders. Coupling results from
genetic field working with modern DNA diagnostic tests such as the
oligonucleotide ligation assay, has enabled us to effectively identify
patients with familial hypercholesterolemia in the German population. We
are now extending genetic field working to hypertension. Hypertension is
much more difficult to study, because the phenotype is more difficult to
discern and document. Both complex diseases have the disadvantage that
the parents of the index patients are likely to already be dead. Neverthe-
less, we concentrate on the recruitment of large pedigrees, sibling pairs
with parents whenever possible, and trios consisting of index patient and
both parents or index patient, parent and sibling. With these constellations
we can conduct association studies, linkage analysis, and novel combina-
tions of both approaches.
Patients at high risk for cardiovascular disease are generally
identified by the presence of risk factors, such as lipid distur-
bances, hypertension, diabetes mellitus, or elevated fibrinogen
values [1, 2]. A positive family history is a well recognized
predictor, since lipid patterns, blood pressure values, type II
diabetes mellitus, and coagulation disturbances are all strongly
influenced by genetic variance [3, 4]. Genetically attuned physi-
cians and geneticists engaged in scientific research have devel-
oped a variety of strategies aimed at defining heritability as well as
at identifying new genes involved in complex polygenic diseases
[5, 6]. Both linkage and novel association studies rely on recruit-
ment of families whose phenotype must be carefully defined.
Family studies permit both linkage analyses with both affected
sib-pair and family data, as well as sophisticated association
approaches such as haplotype sharing or haplotype relative risk
[7]. Less appreciated is the important opportunity the index
patient’s family represents in providing comprehensive preventa-
tive medical care. Obtaining a family history is routine for primary
care physicians, however, the family history is usually only a
cursory exercise and receives at best a few lines in the patient’s
medical records. Family members of patients with complex,
polygenic diseases warrant medical attention, since their risk for
developing the same condition is significantly greater than that of
the general population [3, 4]. We have developed a unique,
simple, approach for recruiting families of patients with cardio-
vascular disease. Our purpose is generally directed at conducting
genetic studies; however, the family tree represents a valuable
patient care tool in terms of prevention. Those family members
found to be at risk are made aware of the necessity for routine
follow-up visits, while those found to have no added risk can be
reassured and spared costly periodic health evaluations.
METHODS
Patients considered to be at high risk for coronary heart disease
by their referring physicians, have been asked to participate in
genetic studies to determine their own risk and the risk of their
family members. Our primary emphasis has been on lipid distur-
bances; however, we recently expanded our recruitment to include
patients with essential hypertension, patients with type II diabetes
mellitus, and patients with “metabolic syndrome,” even if they
have not yet developed overt heart disease. Index patients are
identified on the wards of the hospital and also in the outpatient
clinics. The physician caring for the patient informs the patient
that his condition is likely to be familial and determines whether
or not the patient would be willing to participate in family studies.
We have observed that patients are generally grateful to be
informed that their condition may be influenced by genetic factors
and that they are easily motivated to recruit other family mem-
bers. The family studies have been approved by the university’s
committee on the protection of human subjects, and written,
informed consent is obtained from the index patient as well as
from all participating family members.
The genetic field worker works with the patient to establish the
patient’s medical family tree to the best of the patient’s recollec-
tion. The patient is questioned regarding all of his relatives. The
number of family members and their relationship is determined,
their age, gender, date of birth, or date of death if relevant are
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recorded. The date of any cardiovascular events (stroke, myocar-
dial infarction, documented angina pectoris) or any known car-
diovascular risk factor for each family member is determined. The
primary contact with the patient’s relatives is organized by the
index patient himself. The index patient is given a packet for each
relative containing an explanatory letter, an informed consent
statement to be signed, a questionnaire, a booklet concerning
risks for cardiovascular disease and the nature of family studies,
and two, 10 ml blood cuvettes anticoagulated with EDTA. The
index patient mails the packets or delivers them to his relatives
personally. All relatives agreeing to participate sign the consent
form, complete the questionnaire, and take the blood cuvettes to
their family physician after having fasted overnight. The physician
records the subject’s blood pressure height and weight and draws
the blood. We require the subjects to mail the preaddressed
packets back to us, thereby documenting the voluntary nature of
their participation.
In the department of clinical genetics, the blood is separated,
DNA is extracted from the cells, and the serum is analyzed for
total cholesterol, high density lipoprotein (HDL)-cholesterol, low
density lipoprotein (LDL)-cholesterol, triglyceride concentrations
and Lp(a). Data are transferred from the questionnaire and from
the laboratory into a computer program. Participating family
members receive their own laboratory results, as well as a brief
interpretation. Family members whose values warrant attention
are motivated to seek counseling with the help of their physicians.
Furthermore, each individuals family physician is informed as
well. To maintain confidentiality for other family members, only
the family physician receives a copy of the complete family tree,
albeit without the names and dates of birth of family members not
under his or her care. All participants whose values are abnormal
or borderline, are automatically sent a follow-up questionnaire.
They are questioned with regards to the results of any follow-up
tests or treatment given. In this way, we seek to motivate the
subjects further by emphasizing the important nature of our
activities. The entire concept is illustrated in Figure 1. The
individual steps, such as pedigree drawing, mailings, and analyses
are numbered. From a practical standpoint, these steps are all
computerized. Our study units for genetic approaches are shown
in Figure 2. Multigenerational pedigrees require in general three
generations and more than 10 members. Sibling pairs are either
both affected or discordant. If DNA samples are available from
both parents (complete set), identity by descent can be deter-
mined. DNA from one parent is very helpful, particularly if DNA
from other family members is available. If no DNA from parents
is available, the identity by descent status cannot be determined
unequivocally in all cases. Comparison of genotypes in this case is
based on identity by state. Trios permit parental control studies.
Ideally, the index patient and both parents are recruited. How-
ever, if one parent is missing, the genotype of that parent may be
deduced by genotyping close relatives.
Our eventual purpose is to couple genetic field working with
DNA-based diagnostic tests. For familial hypercholesterolemia,
we have developed an oligonucleotide ligation assay, which effec-
tively identifies 22 LDL receptor mutations identified in German
familial hypercholesterolemia patients. The assay can be in-
creased in capacity fivefold. The technical details of the assay are
described elsewhere [8].
RESULTS
Currently, our entire database comprises 16,869 individuals
from 1137 families of at least three or more members. Index
patients were overwhelmingly receptive, willing, and cooperative,
although some persons we contacted were unable to cooperate
because they were orphaned, had no contact with family members,
the family was not in Germany or for other personal reasons. The
family size was highly variable. The smallest family size included
was defined as three individuals consisting of a set of parents and
one child. The largest family we were able to recruit consisted of
86 family members. The average family size contained 15 individ-
uals. This value included known relatives both dead and alive. The
largest family provided information on 86 persons. From the total
number of 12,566 living relatives, we were able to obtain ques-
tionnaires and blood samples from 2730 persons (22%). Thus,
each participating patient recruited an average of 2.4 additional
relatives.
Table 1 shows the numbers of subjects we have recruited into
the program. We initially concentrated solely on lipid distur-
bances. There are 89 families with at least 10 members with DNA
samples. The total number of sibpairs comprises 1191, including
773 trios. For hypertension studies, our numbers are less. The
phenotype is more difficult to procure and the parents are
frequently not available. We currently have 148 sibpairs with 94
trios.
Currently, our genetic field working program is highly relevant
to patients with familial hypercholesterolemia, which we can
identify with the oligonucleotide ligation assay. We have used this
test to screen patients with high LDL cholesterol values identified
by genetic field working. We have found 32 new individuals with
familial hypercholesterolemia. Each individual represents a new
Fig. 1. Schematic illustration of the genetic
field working concept. The individual steps,
such as pedigree drawing, mailings, and
analyses are numbered. From a practical
standpoint, these steps are all computerized.
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family, the affected members of which all providing an ideal
opportunity for primary disease prevention. Figure 3 shows the
automated genotype analysis of oligonucleotide ligation frag-
ments from a single patient. Figure 4 shows primary representa-
tive data from one oligonucleotide ligation assay experiment with
DNA from 16 patients. Table 2 outlines eight mutations found in
the 32 familial hypercholesterolemia patients and in 34 family
members.
DISCUSSION
We developed a program of genetic field working that is
computer based. The family tree is drawn on the screen, the
patient and family member data are stored in a fashion that they
can be readily retrieved and analyzed, and the patient and the
family members are identified so that no confusion can occur.
Nevertheless, the identity of a participants is protected at every
step. Furthermore, the patient’s right “not to know” is also
preserved.
The strategy of recruiting families from the primary care
environment has the advantage of minimizing ascertainment bias,
in part because of opportunistic case finding. The patients from
the primary care environment are less selected than patients
referred from tertiary care centers. The ascertainment bias asso-
ciated with highly selected populations limits the epidemiological
conclusions that can be drawn. We are aware of the fact that
primary care patient recruitment also involves some ascertain-
ment bias. However, the recruitment of patients from the primary
care environment is considerably less expensive than random
cohort recruitment. In addition, problems with subject confiden-
tiality and data protection are minimized.
Since we are recruiting larger families, we are in a position of
decreasing the ascertainment bias of the index subjects by includ-
ing the members of the family in genetic analyses. In particular,
we are able to utilize the spouses as controls, who are similar to
randomly selected controls and are relatively matched for age and
gender. In this fashion, one can separate families and define case
and control groups for the purpose of association studies. We are
also able to utilize the core families and conduct sibling-pair
linkage studies on the basis of concordance or discordance
(identity by descent). This approach provides the advantage of
permitting both association studies and linkage analysis in the
same cohort. Furthermore, we are in a position to deal with the
problem of locus heterogeneity as well as the difficulty of allelic
heterogeneity. These two features are particularly prominent in
the genetic analysis of the complex diseases.
Studies of lipid disturbances have the advantage that the
genotype and phenotype arrive in the same blood sample. Our
families with familial hypercholesterolemia are an ideal example
of how sensible primary prevention can result from genetic field
working and DNA-based diagnostic testing. Affected family mem-
bers are identified and nonaffected family members can be
reassured. Familial hypercholesterolemia is an example of a
genetic disease for which effective preventative treatment is
available.
However, not all the families we recruited will have a familial
disorder. In some families, only the index patient had elevated
Fig. 2. Study units for genetic approaches. (A) Multigenerational pedi-
grees require in general three generations and more than 10 members. (B)
Sibling pairs, either affected or discordant. If DNA samples are available
from both parents (complete set), identity by descent can be determined.
DNA from one parent is very helpful, particularly if DNA from other
family members is available. If no DNA from parents is available, the
identity by descent status cannot be determined. Comparison of genotypes
in this case is based on identity by state. (C) Trios permit parental control
studies. Ideally, the index patient and both parents are recruited. How-
ever, if one parent is missing, the genotype of that parent may be deduced
by genotyping close relatives.
Table 1. Recruitment of study units
Lipid project
Families
(. 10 members) Sibpairs Twins Trios
Compete 89 294 11 549
One parent 219 2 224
No parents 678 351
Total 1191 364 773
Hypertension
project Sibpairs Sibpairs Twins Trios
Phenotype BP HT BP HT
Complete 141 7 11 55
One parent 113 13 2 39
No parents 171 128 183
Total 425 1248 196 94
On all subjects, both plasma lipids and DNA are available to conduct
genetic studies of hyperlipidemia. Blood pressure (BP) values are avail-
able on almost all subjects. Those with the definite phenotype “hyperten-
sion” (HT) are fewer in number. Furthermore, complete sibpair sets with
parents are more difficult because the parents are usually already dead.
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LDL-cholesterol or triglyceride values or both. Other family
members may or may not have one or the other disturbances or
both. We refer to these index patients as having complex hyper-
lipidemia in that the mode of inheritance does not follow a simple
Mendelian pattern. Some of these persons have secondary hyper-
lipidemia associated with type II diabetes mellitus, thyroid disor-
ders, renal disease, or the ingestion of medications. Family
members of these index patients can be reassured in terms of their
cardiovascular risk. Furthermore, unnecessary subsequent labora-
tory testing can be avoided. We also identified index patients, who
had normal or only marginally elevated lipid values. Some were
found to have abnormal Lp(a) values, a genetic condition for
which we have not searched routinely outside of our family
studies, since it cannot be readily treated.
We have also begun to recruit hypertensive patients. This
condition is more complicated, since hypertension cannot be
readily diagnosed with a single measurement. Our index patients
who were not receiving medications all had 24-hour blood pres-
sure measurements obtained while in the clinic. However, the
parents were frequently no longer living and accurate blood
pressure measurements of other family members were not always
available. We have recruited . 100 families with essential hyper-
tension with two affected siblings within the families. From these
families, we have 149 affected sibling-pairs available. Hyperten-
sion was defined as the ingestion of antihypertensive medications
or $ 3 documented blood pressure values . 145/95 mm Hg
before age 50 years. We have thus far relied on office blood
pressure measurements obtained by the subjects’ physicians. We
are currently field testing the idea of sending a 24-hour ambula-
tory blood pressure measuring device, along with operating
instructions, to selected adult participants who are not ingesting
antihypertensive mediations. The device could then be returned
by mail and the data retrieved in the clinic.
Although association studies are valuable for identifying dis-
ease susceptiblity loci and testing candidate genes [9], we believe
that linkage analysis will prove to be more informative for finding
new genes responsible for hypertension. Cases in point are the
monogenic hypertensive disorders, which have been elucidated by
linkage strategies [10]. Due to the multifactorial nature of hyper-
tension, a large number of hypertensive families will be needed to
detect linkage between any gene loci and variations of blood
pressure. Additional phenotypic data will also need to be taken
Fig. 3. Automated Genotyper analysis of OLA fragments showing representative data from a single patient.
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Fig. 4. Multicolor gel file showing primary data from one OLA experiment with DNA from 16 patients. Publication of this figure in color was made
possible by a grant from Perkin Elmer, Applied Biosystems Division, Foster City, California, USA.
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into account. Particularly important is precise phenotypization of
blood pressure. Our database has similarities to that described by
Charru et al [11] as well as the database collected by Williams et
al [4]. All databases differ in various respects, which provides an
opportunity to appreciate regional, environmental, and perhaps
ethnic differences between populations. Since hospital-based care
and ambulatory care are held strictly separate in Germany, our
approach was developed to facilitate cooperation with our unit
and physicians in practice. We believe our approach is helpful in
melding a cooperation between primary care physicians and
researchers interested in the genetics of cardiovascular disease.
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Eight LDL-receptor mutations were identified in 32 affected persons as
well as 34 asymptomatic familiy members.
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